Alto Neuroscience, INC Schedule 13G passive stakes

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 6.2% of Alto Neuroscience, Inc. common stock, including shares issuable upon warrant exercise.

EcoR1 Capital, LLC and related entities have reported beneficial ownership of 5.8% of Alto Neuroscience, Inc. common stock following the company's recent offering.

Vestal Point Capital, LP and Ryan Wilder have reported a 6.5% passive ownership stake in Alto Neuroscience, Inc., totaling over 2 million shares.

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Alto Neuroscience, Inc. via a Schedule 13G filing.

Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.9% of Alto Neuroscience, Inc. common stock, including shares issuable upon warrant exercise.

Commodore Capital LP and its affiliates have reported a 9.8% beneficial ownership stake in Alto Neuroscience, Inc., totaling 3,190,267 shares.

Perceptive Advisors and Joseph Edelman have reported a 7.3% beneficial ownership stake in Alto Neuroscience, Inc., totaling 1,989,393 shares.

Armistice Capital, LLC and Steven Boyd have disclosed a 6% beneficial ownership stake in Alto Neuroscience, Inc., holding 1,624,000 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.1% passive beneficial ownership stake in Alto Neuroscience Inc.'s common stock.

Point72 Asset Management, its affiliates, and founder Steven A. Cohen have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.0% in Alto Neuroscience, Inc.'s common stock as of March 31, 2025.

K2 HealthVentures Equity Trust LLC and its managing members have disclosed a beneficial ownership of 5.6% in Alto Neuroscience, Inc., primarily through convertible debt and warrants.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 1,600,000 shares, representing 5.91% of Alto Neuroscience, Inc.'s common stock.

RA Capital Management, along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has reported a complete divestment of their beneficial ownership in Alto Neuroscience, Inc., as per a recent Schedule 13G/A filing.

Point72 Asset Management and its affiliates, along with Steven A. Cohen, have disclosed an aggregate beneficial ownership of 8.8% in Alto Neuroscience, Inc. as of December 31, 2024, through a Schedule 13G filing.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.7% of Alto Neuroscience Inc.'s common stock as of December 31, 2024.